Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT01632826 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT01632826
- Sponsor
- Celgene
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.